Gradient Bioconvergence (CEO Nam In-bong), a subsidiary of Gradient, announced on the 29th that it has signed a strategic partnership for precision medicine research with OmicInsight (CEO Yoo Je-gwan), a biotech company in Silicon Valley, USA.
Through this collaboration, the two companies will pursue joint research that combines Gradient Bioconvergence's patient-derived organoid (PDO) platform and OmicInsight's spatial omics analysis technology to precisely elucidate disease mechanisms and increase efficiency in the early stages of new drug development.
Organoids are 3D biomodels that embody actual organ structures based on patient cells. They can reproduce disease pathology and drug responses, making them a key technology for precision medicine research. This collaboration will link Gradient Bioconvergence's large-scale PDO and hiPSC-derived brain organoid resources with OmicInsight's ultra-sensitive spatial transcriptome analysis platform to build an integrated system capable of precisely analyzing cell-level gene expression and interactions.
The two companies expect this system to enable cost-effective spatial analysis and enhance research applicability and scalability by visualizing cellular-level genetic responses and molecular activities at high resolution. It is also expected to be utilized for drug response assessment and biomarker discovery in a variety of fields, including cancer and neurological diseases.
Nam In-bong, CEO of Gradient Bioconvergence, said, “The convergence of spatial biology and organoid technology is a turning point for precisely understanding complex disease biology,” and added, “Through this collaboration, we will expand the resolution and scope of organoid research, contributing to the development of precision medicine.”
“This partnership represents a new leap forward in spatial biology research,” said Yoo Jae-kwan, CEO of Omic Insights. “Our ultra-sensitive platform, combined with Gradient Bioconvergence’s expertise, will provide researchers and clinicians with innovative insights.”
- See more related articles
You must be logged in to post a comment.